Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 263.38 USD 0.84% Market Closed
Market Cap: 141.6B USD
Have any thoughts about
Amgen Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one AMGN stock under the Base Case scenario is 259.2 USD. Compared to the current market price of 263.38 USD, Amgen Inc is Overvalued by 2%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AMGN Relative Value
Base Case
259.2 USD
Overvaluation 2%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.4
P/S
P/S
Price to Sales
4.4
vs History
96
vs Industry
58
Median 3Y
4.9
Median 5Y
5
Industry
7.6
Forward
4.2
More Details
33.5
P/E
P/E
Price to Earnings
33.5
vs History
14
vs Industry
4
Median 3Y
20.6
Median 5Y
19.3
Industry
22.1
Forward
13.6
More Details
19.5
P/OCF
P/OCF
Price to OCF
19.5
vs History
12
vs Industry
8
Median 3Y
13.8
Median 5Y
13.2
Industry
21.9
More Details
23.9
P/FCFE
P/FCFE
Price to FCFE
23.9
vs History
17
vs Industry
8
Median 3Y
9.7
Median 5Y
10.8
Industry
23.4
More Details
18.8
P/B
P/B
Price to Book Value
18.8
vs History
47
vs Industry
2
Median 3Y
24.7
Median 5Y
18.3
Industry
2.5
More Details
5.8
EV/S
EV/S
Enterprise Value to Sales
5.8
vs History
65
vs Industry
44
Median 3Y
6.1
Median 5Y
5.9
Industry
7.5
Forward
5.6
More Details
9.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.6
vs History
19
vs Industry
33
Median 3Y
8.2
Median 5Y
7.8
Industry
9.3
More Details
16
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16
vs History
19
vs Industry
6
Median 3Y
12.9
Median 5Y
11.9
Industry
4.2
Forward
9.6
More Details
30.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
30.4
vs History
11
vs Industry
3
Median 3Y
17.2
Median 5Y
16.4
Industry
4
Forward
12.6
More Details
26.1
EV/OCF
EV/OCF
Enterprise Value to OCF
26.1
vs History
12
vs Industry
6
Median 3Y
16.8
Median 5Y
15.8
Industry
5.9
More Details
30.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
30.1
vs History
12
vs Industry
5
Median 3Y
18.8
Median 5Y
17.4
Industry
3.9
More Details
3
EV/IC
EV/IC
Enterprise Value to IC
3
vs History
36
vs Industry
41
Median 3Y
2.9
Median 5Y
2.9
Industry
4.5
More Details

Multiples Across Competitors

AMGN Competitors Multiples
Amgen Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
133.7B AUD 5.7 31.7 19.6 24.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
36.2B EUR 19.4 -136.2 -110 -80.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.6B USD 15.1 -95.2 -226 -158.8
P/S Multiple
Revenue Growth P/S to Growth
US
Amgen Inc
NASDAQ:AMGN
Average P/S: 3 457 241.3
4.4
26%
0.2
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.4
220%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.1
96%
0.2
P/E Multiple
Earnings Growth P/E to Growth
US
Amgen Inc
NASDAQ:AMGN
Average P/E: 211.6
33.5
73%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.7
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -136.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -95.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Amgen Inc
NASDAQ:AMGN
Average EV/EBITDA: 16.2
16
62%
0.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.6
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -110 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -226 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Amgen Inc
NASDAQ:AMGN
Average EV/EBIT: 21.2
30.4
90%
0.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.5
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -80.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -158.8 N/A N/A

See Also

Summary
AMGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
AMGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AMGN stock valuation using valuation multiples.
Wall Street Estimates
AMGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AMGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.